178 related articles for article (PubMed ID: 8006892)
1. Effects of a novel azaspirane (SK&F 105685) on arthritic lesions in the adjuvant Lewis rat: attenuation of the inflammatory process and preservation of skeletal integrity.
High WB; Bugelski PJ; Nichols ME; Swift BA; Solleveld HA; Badger AM
J Rheumatol; 1994 Mar; 21(3):476-83. PubMed ID: 8006892
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of lymphoproliferative responses by SK&F 105685, a novel anti-arthritic agent.
Kaplan JM; Badger AM; Ruggieri EV; Olivera DL; Newman-Tarr T; Bugelski PJ
J Clin Lab Immunol; 1991 Dec; 36(4):49-58. PubMed ID: 1668843
[TBL] [Abstract][Full Text] [Related]
3. Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610.
Rabinovitch A; Suarez WL; Qin HY; Power RF; Badger AM
J Autoimmun; 1993 Feb; 6(1):39-49. PubMed ID: 8457285
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progression.
Badger AM; Swift BA; Webb EF; Clark RK; Bugelski PJ; Griswold DE
Int J Immunopharmacol; 1993 Apr; 15(3):343-52. PubMed ID: 8505147
[TBL] [Abstract][Full Text] [Related]
5. The effect of SK&F 105685, a novel suppressor cell-inducing compound, in the adjuvant arthritic rat.
Badger AM; Swift BA; Bugelski PJ; High WB; DiMartino MJ; Greig R
Br J Rheumatol; 1991; 30 Suppl 2():66-9. PubMed ID: 1825183
[No Abstract] [Full Text] [Related]
6. Therapeutic activity of SK&F 105685, a novel azaspirane with suppressor-cell inducing activity.
Badger AM; Swift BA
Clin Exp Rheumatol; 1993; 11 Suppl 8():S107-9. PubMed ID: 8324933
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and functional analysis of rat bronchoalveolar macrophages containing chemically induced phospholipid inclusions.
Waites CR; Bugelski PJ; Badger AM
Toxicol Appl Pharmacol; 1995 Feb; 130(2):316-21. PubMed ID: 7871542
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.
Campagnuolo G; Bolon B; Feige U
Arthritis Rheum; 2002 Jul; 46(7):1926-36. PubMed ID: 12124878
[TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug.
Mirshafiey A; Cuzzocrea S; Rehm B; Mazzon E; Saadat F; Sotoude M
Scand J Immunol; 2005 May; 61(5):435-41. PubMed ID: 15882435
[TBL] [Abstract][Full Text] [Related]
11. Induction of nonspecific x-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane.
Schmidbauer G; Hancock WW; Badger AM; Kupiec-Weglinski JW
Transplantation; 1993 Jun; 55(6):1236-43. PubMed ID: 8516808
[TBL] [Abstract][Full Text] [Related]
12. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats.
Lee JC; Dimartino MJ; Votta BJ; Hanna N
J Immunol; 1987 Nov; 139(10):3268-74. PubMed ID: 3500212
[TBL] [Abstract][Full Text] [Related]
13. Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process.
Smith RJ; Sly LM
J Pharmacol Exp Ther; 1996 Jun; 277(3):1801-13. PubMed ID: 8667252
[TBL] [Abstract][Full Text] [Related]
14. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats.
Magari K; Nishigaki F; Sasakawa T; Ogawa T; Miyata S; Ohkubo Y; Mutoh S; Goto T
Inflamm Res; 2003 Dec; 52(12):524-9. PubMed ID: 14991082
[TBL] [Abstract][Full Text] [Related]
15. Antiarthritic and immunoregulatory activity of spirogermanium.
DiMartino MJ; Lee JC; Badger AM; Muirhead KA; Mirabelli CK; Hanna N
J Pharmacol Exp Ther; 1986 Jan; 236(1):103-10. PubMed ID: 2934544
[TBL] [Abstract][Full Text] [Related]
16. Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.
Albrightson CR; Bugelski PJ; Berkhout TA; Jackson B; Kerns WD; Organ AJ; Badger AM
J Pharmacol Exp Ther; 1995 Feb; 272(2):689-98. PubMed ID: 7853183
[TBL] [Abstract][Full Text] [Related]
17. Effects of SK&F 105685, a novel anti-arthritic agent, on immune function in the dog.
Kaplan JM; Badger AM; Ruggieri EV; Swift BA; Bugelski PJ
Int J Immunopharmacol; 1993 Feb; 15(2):113-23. PubMed ID: 8468115
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effects of QFGJS, a preparation from an anti-arthritic herbal formula, on rat experimental adjuvant-induced arthritis.
Cai X; Zhou H; Wong YF; Xie Y; Liu ZQ; Jiang ZH; Bian ZX; Xu HX; Liu L
Biochem Biophys Res Commun; 2005 Nov; 337(2):586-94. PubMed ID: 16199007
[TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis.
Magari K; Miyata S; Nishigaki F; Ohkubo Y; Mutoh S
Inflamm Res; 2004 Oct; 53(10):544-50. PubMed ID: 15597149
[TBL] [Abstract][Full Text] [Related]
20. Disease modifying effects of N-butyryl glucosamine in a streptococcal cell wall induced arthritis model in rats.
Wang SX; Cherian A; Dumitriu M; Grynpas MD; Carran J; Wainman D; Anastassiades T
J Rheumatol; 2007 Apr; 34(4):712-20. PubMed ID: 17309122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
